Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-04
2007-12-04
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C424S468000
Reexamination Certificate
active
11232818
ABSTRACT:
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula:wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-eythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.
REFERENCES:
patent: 4916122 (1990-04-01), Chu
patent: 4957924 (1990-09-01), Beauchamp
patent: 5149794 (1992-09-01), Yatvin
patent: 5190926 (1993-03-01), Chu
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5220003 (1993-06-01), Jung et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5539116 (1996-07-01), Liotta
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5559101 (1996-09-01), Weis et al.
patent: 5565438 (1996-10-01), Chu
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu
patent: 5939402 (1999-08-01), Weis et al.
patent: 5990093 (1999-11-01), Schinazi et al.
patent: 6025335 (2000-02-01), Weis et al.
patent: 6194391 (2001-02-01), Schinazi et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 6297222 (2001-10-01), von Borstel et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 6569837 (2003-05-01), Gosselin et al.
patent: 2206878 (1997-03-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 355 131 (1996-09-01), None
patent: 875971 (1961-08-01), None
patent: 6-293645 (1994-10-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 89/03838 (1989-05-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 62/08727 (1992-05-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 94/01138 (1994-01-01), None
patent: WO 94/20523 (1994-09-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 96/11204 (1996-04-01), None
patent: WO 96/13512 (1996-05-01), None
patent: WO 96/15132 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 99/45935 (1999-09-01), None
patent: WO 00/09531 (2000-02-01), None
Arner, E.S.J., et al., “Mammalian Deoxyribonicleoside Kinases,”Pharm. Ther., 67(2), 155-186 (1995).
Berk, A.J., et al., “A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria,”J Biol Chem, 248(8):2722-2729 (1973).
Bestwick, R.K., et al., “Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells,”J. Biol. Chem., 257(16):9300-9304 (1982).
Bloch, A., et al. “The Role Of The 5′-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase,”J. Med. Chem., 10(5):908-12 (Sep. 1967).
Bridges, E.G., et al., “Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria,”J. Biol. Chem., 274(8):4620-4625 (Feb. 19, 1999).
Bridges, E.G., et al., “Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs,”Proc. Am. Assoc. Cancer Res., 38:414 (Mar. 1997).
Bridges, E.G., et al., “Inhibition of Mammalian DNA Polymerase-Associated 3′ to 5′ Exonuclease Activity by 5′-Monophosphates of 3′-Azido-3′-Deoxythymine and 3′-Amino-3′-Deoxythymidine,”Biochemical Pharmacology, 45(8):1571-1576 (1993).
Bryant, M.L., et al., “Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection,”Antimicrobial Agents and Chemotherapy, 45(1):229-235 (Jan. 2001).
Chang, C.N., et al., “Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (−)-2′,3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication,”Journal of Biological Chemistry, 267(20):13938-13942 (Jul. 15, 1992).
Chang, C.-N., et al., “Biochemical Pharmacology of (+)- and (−)-2′, 3′-Dideoxy-3′-thiacytidine as Anti-hepatitis B Virus Agents,”J Biol Chem, 267(31), 22414-22420 (Nov. 5, 1992).
Chariot, P., et al., “Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion,”J. Hepatology, 30:156-160 (1999).
Chen, M.S., et al., “Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus,”J Virol., 30(3):942-945 (Jun. 1979).
Chen, C.-H., et al., “Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytidine,”J. Biol. Chem., 264(20):11934-11937 (Jul. 15, 1989).
Chen, C.-H., et al., “The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytine,”J. Biol. Chem., 267(5): 2856-2859 (Feb. 15, 1992).
Cui, L., et al., “Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells,”J. of Pharmacology and Experimental Therapeutics, 280(3):1228-1234 (1997).
Davis, A.F., et al., “In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells,”J Cell Biol, 135(4), 883-893 (Nov. 1996).
Davisson, V.J., et al., “Synthesis of Nucleotide 5′-Diphosphates from 5′-O-Tosyl Nucleosides,”J. Org. Chem., 52(9):1794-1801 (1987).
Doong, S.-L., et al., “Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues,”Proc. Natl. Acad. Sci. USA, 88:8495-8499 (Oct. 1991).
Du, J., et al, Synthesis, “Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides,”J. of Med. Chem., (40)19:2991-2993 (Sep. 12, 1997).
Dutschman, G.E., et al., “Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-βL-(−)-5-Fluorocytidine and Its Activity in Combination with Climically Approved Anti-Humna Immunodeficiency Virus β-D-(+) Nucleoside Analogs In Vitro,”Antimicrobial Agents and Chemotherapy, 42(7), 1799-1804 (Jul. 1998).
Farci, P., et al., “Treatment of chronic hepatitis D with interferon alfa-2a,”New England Journal of Medicine, 330(1):88-94 (Jan. 13, 1994).
Fujimori, S., et al., “Enantio-oligodeoxyribonucleosides,” Symposium on Nucleic Acids Technology,Nucleic Acids Research Symposium Series, 22:97-98 (1990).
Furman, P.A., et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers ofcis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine&#x
Bryant Martin L.
Gosselin Gilles
Imbach Jean-Louis
Centre National de la Recherche Scientifique
Idenix Pharmaceuticals Inc.
Jones Day
L'Université Montpellier II
Peselev Elli
LandOfFree
β-L-2′-deoxy-nucleosides for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β-L-2′-deoxy-nucleosides for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-L-2′-deoxy-nucleosides for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874041